There is also an ongoing phase 2 study evaluating the effects of an anti-TGF-β antibody (LY2382770) on the change in serum creatinine levels from baseline to 12 months in patients with type 1 and type 2 diabetes with diabetic nephropathy, the results of which have not yet been reported [142]. This evidence concerns the gene TGFB1 and diabetic kidney disease.